Pharmacogenomics for the efficacy of platinum-based chemotherapy: Old drugs, new integrated perspective.
Biomed Pharmacother
; 126: 110057, 2020 Jun.
Article
em En
| MEDLINE
| ID: mdl-32145590
ABSTRACT
Platinum-based chemotherapy remains the cornerstone of treatment for many malignancies. However, although therapeutic efficiency varies greatly among individuals, there is a lack of pharmacogenomic biomarkers that can be used in clinical settings to identify chemosensitive patients and allow stratification. With the development of high-throughput screening techniques and systems biology approaches, a growing body of evidence has shown that platinum resistance is a multifactorial, multi-dimensional, dynamic process incorporating genetic background, tumor evolution and gut microbes. This review critically summarizes potential pharmacogenomic biomarkers for predicting the efficacy of platinum drugs and provides a comprehensive, time-varying perspective that integrates multiple markers.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Farmacogenética
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Biomarcadores Tumorais
/
Carboplatina
/
Cisplatino
/
Variantes Farmacogenômicos
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article